

Rec'd PCT/PTO 05 SEP 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Nicholas Bachynsky Woodie Roy

Serial No.: 09/744622 (PCT/US99/16940)

Filed: January 26, 2001

For: CHEMICALLY INDUCED

INTRACELLULAR HYPERTHERMIA

RECEIVED

19 SEP 2001

Logar Graff International Division

Examiner: Unassigned

Group Art Unit: Unknown

Atty. Docket: P01615US1 / 09805783

(U.S. Nat'l. Phase)

PETITION UNDER 37 CFR 1.47

Texas Pharmaceuticals, Inc., assignee of the whole interest in the above-referenced invention, respectfully requests that a declaration signed by assignee be accepted in fulfillment of the Notification of Missing Parts Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office mailed March 5, 2001. The inventors in the above-referenced application have refused to execute a current Declaration in this application after numerous attempts have been made to have them execute one, although they signed one when the provisional application on which the above-identified application is based was filed. Their refusal apparently stems from a dispute between them and the owner of the application, Texas Pharmaceuticals, Inc.. The inventors executed assignments of the invention to Texas Pharmaceuticals, Inc., copies of which are attached as Exhibit A. The earlier signed declaration is attached as Exhibit B. The general attorney for Texas Pharmaceuticals, Inc. advised the undersigned that the inventors would not sign a current declaration and refused to accept letters by certified mail.

Thus, in order to preserve the rights of the parties and to prevent irreparable harm by allowing the application to become abandoned, it is necessary to accept a declaration signed by

25015073.1

11/09/2001 UEDUVIJE 00000036 062375 09744622

01 FC:154

130.00 CH

the assignee of the application, Texas Pharmaceuticals, Inc. prior to the expiration of the time period set for submission.

The last known addresses of the inventors are:

Nicholas Bachynsky 5944 Coral Ridge Drive, Suite No. 202 Coral Springs, FL 33076

Woodie Roy 5944 Coral Ridge Drive, Suite No. 202 Coral Springs, FL 33076

Please charge the deposit account of Fulbright & Jaworski LLP, Account No. 06-2375, for the petition fee of \$130.00 and any additional fees that may be necessary.

09/13/2001 SNAJARRO 00000073 062375 0974462

01 FC:122

130.00 CH

Respectfully submitted,

Paul E. Krieger

Registration No.: 25,886

Data

FULBRIGHT & JAWORSKI L.L.P.

1301 McKinney, Suite 5100

Houston, Texas 77010-3095

Phone: (713) 651-7732 FAX: (713) 651-5246



Exhibit 1



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to BOX: PCT; Assistant Commissioner for Patents, Washington, D.C. 20231 on 17 July 2000

Colby S. Delgado

O Signature

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Nicholas Bachynsky

Woodie Roy

Serial No.: PCT/US99/16940

Filed: July 27, 1999

For: CHEMICALLY INDUCED INTRA-

CELLULAR HYPERTHERMIA

§

Atty. Docket: P01615WO0 / 09805783

Box: PCT

Assistant Commissioner for Patents

Washington, D.C. 20231

TRANSMITTAL LETTER

Dear Sir:

Enclosed for filing in the above-identified international application are the following:

- Assignment executed by Nicholas Bachynsky on March 4, 1998 and Recordation Form Coversheet;
- Assignment executed by Woodie Roy on July 21, 1998 and Recordation Form Coversheet;
- Check in the amount of \$80.00; and
- Return postcard.

Please charge any additional fees and/or credits to the deposit account of Fulbright & Jaworski L.L.P. under account number 06-2375/09805783, from which the undersigned is authorized to draw. A duplicate of this letter is enclosed for accounting purposes.

Respectfully submitted,


Date: 1) (1/1/20

David L. Fox, Ph.D.

Reg. No. 40,612

FULBRIGHT & JAWORSKI L.L.P. 1301 McKinney, Suite 5100 Houston, Texas 77010-3095

Phone: 713-651-8231



RECORDATION FORM COVER SHEET

3EF U 5 2001	
To the Honorable Commission Please record the attached orig	er of Patents and Trademarks: inal documents or copy thereof.
Name of conveying party(ies): Nicholas Bachynsky	2. Name and address of receiving party(ics):
•	Name: Texas Pharmaceuticals, Inc.
Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No	Internal Address:
2 103 - 100	Street Address: 701 W. 4th Street
·	City: Texarkana
	State: TX Zip: 75501
3. Nature of Conveyance:	
☐ Assignment ☐ Merger	
☐ Security Agreement ☐ Change of Name	
□ Other	Additional name(s) & address(es) attached?
Execution Date: March 4, 1998	□ Yes ⊠ No
4. Application number(s) or patent number(s): PCT/US99	/16940
If this document is being filed together with a new appl execution date of the application is:	
A. Patent Application No.(s):	B. Patent No.(s)
Additional numbers atta	ached? Tyes No
5. Name and address of party to whom correspondence concerning document should be mailed:	6. Total number of applications and patents involved: 1
Name: David L. Fox	
Internal Address: Fulbright & Jaworski LLP	7. Total fee (37 CFR 3.41): \$ 40.00
Street Address: 1301 McKinney	⊠ Enclosed
Suite 5100	☐ Authorized to be charged to deposit account
City: Houston	8. Deposit account number:
State: TX Zip: 77010-3095	6. Deposit account named:
	(Attach duplicate copy of this page if paying by deposit account)
DO NOT US	E THIS SPACE
9. Statement and signature. To the best of my knowledge and belief, the foregoing i true copy of the original document.	nformation is true and correct and any attached copy is a
David L. Fox Name of Person Signing	Signature 17 July 2000 Date
Manie of a croom premine	8

Total number of pages including cover sheet, attachments, and document.

ASSIGNMENT

DATE:

March 4, 1998

ASSIGNOR:

NICHOLAS BACHYNSKY

701 W. 14th Street

Texarkana, Texas 75501

ASSIGNEE:

TEXAS PHARMACEUTICALS, INC., a Texas corporation

701 W. 14th Street

Texarkana, Texas 75501

In consideration of Ten Dollars (\$10.00) cash in hand paid to me and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, I, NICHOLAS BACHYNSKY (hereinafter called "Assignor"), who have made an invention of a novel use and method of inducing intracellular hyperthermia and free radical flux through the use of dinitrophenol and other mitochondrial uncoupling agents in the treatment of infectious and malignant disease, assign, sell, transfer and convey to TEXAS PHARMACEUTICALS, INC., a Texas corporation, whose address is 1314 Main Street, Texarkana, Bowie County, Texas 75501 (hereinafter called "Assignee"), its successors and assigns, Assignor's entire right, title and interest in and to the following rights, interest, and property (hereinafter collectively called the "Rights"):

- 1. Assignor's invention of uses, methods and therapies of inducing intracellular hyperthermia and free radical flux through the use of dinitrophenol and other mitochondrial uncoupling agents in the treatment of infectious and malignant disease, including without limitation Assignor's rights, powers, interests and title in and to the methods, uses and processes described in Schedule 1 attached to this Assignment, (collectively, herein called the "Invention").
- 2. All applications for patent or like protection on said Invention that have been

or may in the future be made by Assignor or Assignor's legal representatives, in any and all countries.

- 3. All patents and like protection that have been or may in the future be granted on said Invention to Assignor or Assignor's legal representatives, in any and all countries of the world.
- 4. All substitutions for and divisions, continuations, continuations-in-part, renewals, reissues, extensions and the like of said applications and patents and similar rights or grants, including, without limitation, those obtained or permissible under past, present and future law and statutes.
- All rights of action on account of past, present and future authorized or unauthorized use of said Invention and for infringement of said patents and like protection.
- 6. The right of Assignee to file in his name disclosure documents, applications for patents and like protection for said Invention in any country and countries in the world.
- 7. All international rights of priority associated with said Invention, disclosure filings, applications, patents and like protection.

TO HAVE AND TO HOLD the Rights unto the Assignee, its successors and assigns forever, and Assignor does hereby bind himself, his heirs, legal representatives and assigns, to forever WARRANT and DEFEND the title to the Rights unto the said Assignee, its successors and assigns, against any person whomsoever lawfully claiming, or to claim the same, or any part thereof.

Assignor covenants and agrees that Assignor will cooperate with Assignee such that Assignee may enjoy to the fullest extent the benefit of this Assignment. Such cooperation shall include, but not limited to, all of the following:

- 1. Assignor's prompt execution of all papers that are deemed necessary or desirable by Assignee to perfect the right, title and interest herein conveyed, and
- 2. Assignor's prompt execution of all petitions, oaths, specifications, declarations

or other papers that are deemed necessary or desirable by Assignee for filing and prosecuting patent applications, for filing and prosecuting substitute, division, continuing, or additional applications in the United States and/or all foreign countries, for filing and prosecuting applications for reissuance or reexamination of letters patent, and for interference proceedings involving and covering any of the Rights, and

3. Assignor's prompt assistance and cooperation, including but not limited to execution of documents and testifying, in the prosecution of legal proceedings involving any of the Rights, including, but not limited to, patent prosecution, interference proceedings, infringement court actions, opposition proceedings, cancellation proceedings, priority contests, unfair competition court actions, trade secret court actions, public use proceedings, slander, license breach and royalty collection proceedings and other legal proceedings.

Assignor warrants that Assignor has the right to make the assignment set forth herein and that no other person or entity has any rights of ownership or claim to the subject matter of this Assignment. This Assignment is binding upon Assignor, Assignor's heirs, administrators, executors, successors, trustees, devisees and assigns and inures to and for the benefit of Assignee, its successors and assigns.

EXECUTED effective as of the date first above written and at the time and place indicated below opposite the signature:

NICHOLAS BACHYNSKY

Date: 3/9/90

STATE OF TEXAS
COUNTY OF BEXAR

BEFORE ME, the undersigned authority, on this day personally appeared NICHOLAS BACHYNSKY known to me to be the person whose name is subscribed to the foregoing instrument, and acknowledged to me that he executed the same for the purposes and consideration therein expressed.

GIVEN UNDER MY HAND AND SEAL OF OFFICE, this the 5th day of March, 1998.

A LYRGINIA OHLENBUSCH My commission expires May 4, 2000 Verginia Ohlenbusch

Notar Public Signature

Virginia Ohlenbusch
Notary Printed Name

Commission Expires: 5-4-2000



SCHEDULE 1 TO ASSIGNMENT


INVENTION

This invention provides a medical method for: (1) prevention of life threatening hypothermia; (2) enhancing magnetic resonance spectroscopy and positron emission tomographic metabolic imaging; and (3) treatment of resistant neoplastic and infectious disease by concurrent administration of dinitrophenol [or other mitochondrial thermoregulatory uncoupling agents, e.g., carbonylcyanide m-chorophenylhydrazone (CCCP), carbonylcyanide-p-trifluoromethoxy-phenylhydrazone (FCCP), recombinant brown fat type protein, or lipid proton ionophores] and respiratory oxygen, intravenous fluids, anti-platelet drugs, as needed cooling, and specific metabolic, activating cytokines [e.g., recombinant tumor necrosis factor (TNF), interferons, etc.], hormones (e.g., glucagon), and other medications to control and focally enhance the mitochondrial uncoupling effects.

The present invention avoids the use of labor intensive, complex hyperthermia equipment, including invasive extracorporeal perfusion, with its associated thermal gradient toxicity problems to interposed normal tissues, inherent to all therapeutic methods of delivering heat from the outside-in. A new use(s)/method of generating intracellular oxygen derived free radicals, and heating from within the cell has been discovered for dinitrophenol (or other oxidative phosphorylation uncouplers) in prevention of cold injury, and treatment of free radical-thermosensitive parasites (e.g., Echinococcus), bacteria (e.g., Borrelia burgdorferi), lipid enveloped viruses (e.g., HIV), and neoplasia (e.g., gastric adenocarcinoma). It has further been discovered that cataracts, induced by dinitrophenol in the treatment of chronic obesity, can be prevented by concomitant administration of a variety of free radical scavenging agents, including tocopherol, ascorbic acid, and beta-carotene.

Briefly, the present invention is a new use(s)/method of inducing increased, intracellular free radical flux and hyperthermia, including the procedure of administrating dinitrophenol to patients in doses sufficient to denature and inactivate targeted biologic systems. Concurrent administration of tissue selective activating hormones, biologicals or drugs permits greater enhancement of the therapeutic index, while physiologic gain cooling, fluids, respiratory oxygen, and monitoring procedures permit safe therapeutic control. The figure on the attached page depicts an example use(s)/methodology of this process in an algorithm.

SCHEMATIZED MITOCHONDRIAL UNCOUPLING METHOD MALIGNANT DISEASE FOR DIAGNOSIS (REATMENT OF INFECTIOUS A



- * Confirmed Diagnosis by culture, PCR, or histopathology; specific serology.
- * Known Temperature and Heating Time required for inactivation, e.g., Treponema pallidum (syphilis)-41.5°C @ 1 hour; Borrelia burgdor-feri (Lyme Disease)-41.5°C @ 1 hour; Echinococcus multilocularis (Hydatid infestation)-41°C @ 15 minutes; HIV, chronically infected (provirus) cells (tissue culture)-42°C @ 10 hours, with recombinant TNF-a, 42°C @ 3 hours. Kaposi's sarcoma, HIV infection in the patient-42°C @ 2 hours/44°C @ 15 minutes.
- * Unknown Temperature and Heating Time required for inactivation of meoplasms, or other infectious agents, determined by predictive - assay of biopsy/culture; generally, treatment temperature/time will be decreased due to endogenous uncoupling also occurring in targeted biologic system (except viral).

- * Bistory of cardiac, hepatic, pulmonary renal, CNS, malignant hyperthermia, or endocrine disease, i.e., exclusion of patients-congestive heart failure, severe dysrhythmias; alcoholic or other hepatitis with elevated bilirubin/enzymes; known endocrinopathies of brittle diabetes, pheochromocytoma, etc.; medications known to stimulate the physiologic response of hypermetabolic state and hyperthermia, e.g., vascular constrictors, anticholinergics, calcium channel blocker, etc.
- * Pulmonary, renal, hepatic function tests; chest X-ray; CBC with platelet count; Chem profile with Ca++, Mg++, PO4=; exercisemultigated cardiac radionucleotide scan with resting ejection fraction of at least 45%, and no deterioration upon exercise.
- * Enhancing or sensitizing agents to increase therapeutic gain, i.e., use of ionizing radiation, chemotherapy, drugs, or biologic modifiers (synergistic or additive).

METHOD PROTOCOL MANAGEMENT TREATMENT BASELINE & MONITORED

- * Dinitrophenol, dosage & schedule * on "Biologic/Clinical Criteria"; IV (or IM-SC) test dose (lmg/kg) by VO2 response-lml O2/sec=20watts; common IV dosage, 1-5mg/kg, q i-4 hr, dissipation modify dose/schedule.
- * Other mitochondrial uncoupling agents, increased potency/more localized effect, e.g., FCCP, CCCP, 6847; long chain fatty acids, and brown fat "thermogin", etc.
- * Modulating-controlling agents, tissue specific mediators which modulate substrate turnoverrates through Krebs cycle; glucagon, .5-10mg/hr-IV; dopamine(1-10 micrograms/kg/min); insulin-dose based micrograms/kg/min); amrinone(5-7.5 serum creatinine. micrograms/kg/min); isoproterenol (.5-2 micrograms/min).

- Oxygen consumption/increase, precedes core temperature increase by 4 minutes; prolonged or high risk patient-additional monitoring of tissue oxygenation by gastric pH, NMR, PET or infrared spectroscopy, ear oximetry, blood gas.
- PO 2X greater q 6-12 hr; BMR & heat * Core temperature, esophageal, rectal, bladder catheter thermistors.
 - Cardiac function, continous display of thythm, * Intravenous fluids, i.e., .85% Saline, race, blood pressure and respiratory race; Swan-Ganz catheter for high risk patient.
 - per kg /hour; observe for possible myoglobinuria urinary losses, maintain BP. and monitor fluid input/output.
 - * Depatic function tests, at target temperature; iosoenzyme fractionation if tumor lysis is a consideration.
 - * CNS agitation, anxiety, possible seizure prophylaxis.
- on blood glucose; dobutamine(1-15 * Blood chemistry/electrolytes-glucose, PO4,

- Oxygen (100%) @ 4-6 liters/minute via nasal cannula/face mask.
- * Heat control with evaporation preventing water absorbing blankets/plastic liners; cooling control-if needed with tepid H2C spray and/or fan evaporative loss; use c P.O. propylthiouracil (PTU); Decadron-I.
- D_W = NS, supplemented with appropriate milliequivalents of K+, PO4 , Mg++; flui perfluorooctane sulfonamide, SF- * Renal output/function, maintain at least 1-1.5ml rate to compensate for evaporative and
 - Arrhythmia control, if needed-use of nor negative inotropic, or drugs that cannot cause cardiac decompensation in hypermet bolic state e.g., lidocaine; avoidance c beta blockers and Ca++ channel blockers
 - Anxiety, possible seizure control with I.V. valium, thiopental; avoidance of drugs with acropine like effects or majo anti-psychotic drugs.

Sensitivity increased by enhanced metabolic differenc between diseased/normal tissues, i.e., 0, glucose, fat acid, ATP, phosphocreatine & specific substrate consumates. ion; lactic acid, free radical production; early diag-& predictability of disease treatment parameters/suc-

DNE-IA 6 Imsiks (5X-AO⁵) DIACNOSIS - Enhancement of NMR, PET, & Near-Infrared Spectroscopy. THERAPY OF INFECTIOUS MEDICAL USES DNP-IV @ 2-5mg/kg

93-6hr for 2x-Vo

→PARASITIC (See Illustrative Example)

41.5°C/1 hr (or less) BACTERIAL (Borrelia burgdorferi) 42°C/2 to 8 hrs (or less) --- VIRAL (HIV)

Based on predictive biopsy and use of radiation, NEOPLASTIC chemotherapy or biologic response modifiers

& HALICHANT DISEASE (dosage/frequency of uncoupling agent vill be determined by the specific agent treated & use of modulating,

enhancing, or other combined therapy drugs.

ILLUSTRATIVE METHOD/USE EXAMPLE -

A 52 year old white Swiss male, hunting dog trainer, presented with right upper quadrant abdominal pain. History revealed past(24 month old) hepatic "cyst" surgery and treatment with albendazole(only 1 dose was given because of anaphylactic reaction). He denied history of weight loss, pulmonary, cardiac or neurologic disease. Upon physical examination, he had a weight of 198 pounds (90 Kg), height of 5'll", blood pressure 140/80, pulse-76 and regular, respirations 18/minute, and oral temperature of 37.3°C. Laboratory studies, including hepatic, renal, pulmonary and cardiac function tests were normal; complete blood count was unremarkable except for 20% eosinophilia. Ultrasound and nuclear magnetic resonance of the liver revealed 4 (2-3 cm. in diameter) cysts in the mid-right lobe; ELISA serology showed a diagnostic titer specific for Hydatid disease with Echinococcus multilocularis. The patient refused to entertain any additional surgery or albendazole therapy.

After clinical assessment and treatment evaluation, i.e., Echinococcus multilocularis protoscoleces and germinal layers are destroyed at 41°C/15 minutes, whereas liver-hepatocytes withstand temperatures of 42°C to 44°C for known periods of 20 hours and 15 minutes respectively, the patient was given 1 aspirin; 10 mg. diazepam by mouth; and, intravenous fluids of 0.85 normal saline containing 9 millimolar K₂PO₄, 7 milliequivalents of K⁺, and 2cc of 50% saturated solution of Mg₂SO₄/liter, were infused at a rate of 12cc/kg/hr. Urine output was maintained at 1cc/kg/hour or greater. Esophageal (optional), rectal and foley (16 gauge) tipped bladder catheter thermistors gave temperature readings every two minutes within 0.1°C. Cardiac rate, rhythm, blood pressure, and repiratory rate sensors were placed and continously displayed on a multichannel monitor. Intravenous glucagon-2mg/hr was infused, with 1 mg given prior to DNP.


The patient was covered with a water absorbing polyethelene lined blanket, and baseline respiratory gas flow/oxygen consumption (VO₂) was determined using a 3 minute bag collection. Five minutes after intravenous administration of 90 mg of dinitrophenol (2% DNP/5% NaHCO₃ at 1 mg/kg), and determination that there was no untoward or idiosyncratic reaction, an additional 90 mg of 2,4 dinitrophenol (total of 180mg, 2mg/kg body weight) was infused. Monitored physiologic parameters are shown in the Table below. An additional VO₂ rate was obtained five minutes after the second dose of DNP and the patient was thereafter placed on 100% O₂ via nasal canula. Target core temperature was maintained by occasional exposure of a limb and/or decreasing the glucagon infusion rate to 0.25 mg/hour. After the patient was maintained at a core temperature of 41.3°C for 20 minutes, the treatment was terminated by removing the blanket and permitting evaporative and radiant heat loss to return the body temperature to a normothermic level.

TABLE

Monitored Clinical Data On Mitochoodrial Uncoupling Use/Method In Illustrative Example
(Treatment of Hydatid disease-Echinococcus multilocularis)

		(Treatment of i	iydatid diseas	e-Echinococcus mul	£110cn19112\		
Time (pinutes)	Medication (type & dose)	Resp. Rate-0 ₂	Consumption (ml/min)	Cardiac Rate (beats/min)	Urine Output (total mi)	Core Temp.	Other (remarks)
-60	I.V. Fluids85%	18	290	78	•	37.1	Fluids @ 10-12cc per kg/hour.
-30	NS @ G.B L/hour Glucazon-IV Drip	20	•	78	. 47	37.1	Repatic Krebs Cyclestisulation.
0	@ 2mg/hour 2.4-dinitrophenol-90=2	20	-	88	58	37.4	Covered with poly- ethylene blanker.
2	IV in 4.5ml of SINAHCO3 [prepared by dissolving 2.3cm DNP(15Z H ₂ O) in SI NAHCO3-giving 2Z solution	24 (n)	350	. 92	-	37.8	Increased 0, con- sumption precedes temp. elevation.
5	2,4-dimitrophenol-90cz IV in 4.5ml of 5XNaHCO;	26	-	98	-	37.8	
10	Fluids increased to 1.2 L/hour; start 02	30	630	110	15	39.4	After VOzdetermine 1002 Oz @ 4 L/min via nasal cannula.
20	•	30	-	120	18	40.3	
40	Glucagon -IV Drlp	30 ,	-	138	28	41.4	Lover extremity is partially exposed.
	decreased to 0.5mg/hr		_	140	30	41.2	Blanket removed
60 120	Glucagon discontinued IV fluid discontinued	30 24	-	100	98	38.4	All thermistors

If Variations of the above use/method, i.e., protocol evaluation, monitoring, medications/dosages, time & temperature of mitochondrial uncoupling, will be necessitated by clinical and targeted biologic system treatment factors. Such variations for treatment of other parasitic (e.g. Halaria), bacterial (e.g., Lyne, Hansens disease), viral (e.g., HIV) and neoplastic disease will occur to those skilled in the art of medicine, and will be more fully described in the patent application.



RECORDATION FORM COVER SHEET

SEP 5 2001 To the Honorable Commission	ner of Patents and Trademarks:
5 O/ .	inal documents or copy thereof.
1. Woodie Roy Additional name(s) of conveying party(ies) attached?	Name and address of receiving party(ies): Name: Texas Pharmaceuticals, Inc.
☐ Yes ☒ No	Internal Address:
_ 103 _ 110	Street Address: 701 W. 4th Street
	City: Texarkana
	State: <u>TX</u> Zip: 75501
3. Nature of Conveyance:	
⊠ Assignment □ Merger	
☐ Security Agreement ☐ Change of Name	·
☐ Other	Additional name(s) & address(es) attached?
Execution Date: July 21, 1998	☐ Yes ⊠ No
4. Application number(s) or patent number(s): PCT/US99/	16940
If this document is being filed together with a new appliexecution date of the application is:	cation, the
A. Patent Application No.(s):	B. Patent No.(s)
Additional numbers atta	ched? ☐ Yes No
5. Name and address of party to whom correspondence concerning document should be mailed:	6. Total number of applications and patents involved: 2
Name: David L. Fox	
Internal Address: Fulbright & Jaworski LLP	7. Total fee (37 CFR 3.41): \$ 40.00
Street Address: 1301 McKinney	☑ Enclosed
Suite 5100	☐ Authorized to be charged to deposit account
City: Houston	8. Deposit account number:
State: TX Zip: 77010-3095	
DO MONTAN	(Attach duplicate copy of this page if paying by deposit account)
DO NOT USE	THIS SPACE
9. Statement and signature. To the best of my knowledge and belief, the foregoing instrue copy of the original document.	formation is true and correct and any attached copy is a
David L. Fox	17 July 2000
Name of Person Signing	Signature / Date
	O

Total number of pages including cover sheet, attachments, and document.

ASSIGNMENT

DATE:

July 21, 1998

ASSIGNOR:

WOODIE ROY

c/o 701 W. 14th Street Texarkana, Texas 75501

ASSIGNEE:

TEXAS PHARMACEUTICALS, INC., a Texas corporation

701 W. 14th Street

Texarkana, Texas 75501

In consideration of Ten Dollars (\$10.00) cash in hand paid to me and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, I, WOODIE ROY (hereinafter called "Assignor"), who have made an invention of a novel use and method of inducing intracellular hyperthermia and free radical flux through the use of dinitrophenol and other mitochondrial uncoupling agents in the treatment of infectious and malignant disease, assign, sell, transfer and convey to TEXAS PHARMACEUTICALS, INC., a Texas corporation, whose address is 1314 Main Street, Texarkana, Bowie County, Texas 75501 (hereinafter called "Assignee"), its successors and assigns, Assignor's entire right, title and interest in and to the following rights, interest, and property (hereinafter collectively called the "Rights"):

1. Assignor's invention of uses, methods and therapies of inducing intracellular hyperthermia and free radical flux through the use of dinitrophenol and other mitochondrial uncoupling agents in the treatment of infectious and malignant disease, including without limitation Assignor's rights, powers, interests and title in and to the methods, uses and processes described in Schedule 1 attached to this Assignment, (collectively, herein called the "Invention").

- 2. All applications for patent or like protection on said Invention that have been or may in the future be made by Assignor or Assignor's legal representatives, in any and all countries.
- 3. All patents and like protection that have been or may in the future be granted on said Invention to Assignor or Assignor's legal representatives, in any and all countries of the world.
- 4. All substitutions for and divisions, continuations, continuations—in—part, renewals, reissues, extensions and the like of said applications and patents and similar rights or grants, including, without limitation, those obtained or permissible under past, present and future law and statutes.
- 5. All rights of action on account of past, present and future authorized or unauthorized use of said Invention and for infringement of said patents and like protection.
- 6. The right of Assignee to file in his name disclosure documents, applications for patents and like protection for said Invention in any country and countries in the world.
- 7. All international rights of priority associated with said Invention, disclosure filings, applications, patents and like protection.

TO HAVE AND TO HOLD the Rights unto the Assignee, its successors and assigns forever, and Assignor does hereby bind himself, his heirs, legal representatives and assigns, to forever WARRANT and DEFEND the title to the Rights unto the said Assignee, its successors and assigns, against any person whomsoever lawfully claiming, or to claim the same, or any part thereof.

Assignor covenants and agrees that Assignor will cooperate with Assignee such that Assignee may enjoy to the fullest extent the benefit of this Assignment. Such cooperation shall include, but not limited to, all of the following:

1. Assignor's prompt execution of all papers that are deemed necessary or desirable by Assignee to perfect the right, title and

interest herein conveyed, and

- 2. Assignor's prompt execution of all petitions, oaths, specifications, declarations or other papers that are deemed necessary or desirable by Assignee for filing and prosecuting patent applications, for filing and prosecuting substitute, division, continuing, or additional applications in the United States and/or all foreign countries, for filing and prosecuting applications for reissuance or reexamination of letters patent, and for interference proceedings involving and covering any of the Rights, and
- 3. Assignor's prompt assistance and cooperation, including but not limited to execution of documents and testifying, in the prosecution of legal proceedings involving any of the Rights, including, but not limited to, patent prosecution, interference proceedings, infringement court actions, opposition proceedings, cancellation proceedings, priority contests, unfair competition court actions, trade secret court actions, public use proceedings, slander, license breach and royalty collection proceedings and other legal proceedings.

Assignor warrants that Assignor has the right to make the assignment set forth herein and that no other person or entity has any rights of ownership or claim to the subject matter of this Assignment as of the date of this Assignment. This Assignment is binding upon Assignor, Assignor's heirs, administrators, executors, successors, trustees, devisees and assigns and inures to and for the benefit of Assignee, its successors and assigns.

EXECUTED effective as of the date first above written and at the time and place indicated below opposite the signature:

Date:

STATE OF TEXAS COUNTY OF BOWIE

BEFORE ME, the undersigned authority, on this day personally appeared WOODIE ROY known to me to be the person whose name is subscribed to the foregoing instrument, and acknowledged to me that she executed the same for the purposes and consideration therein expressed.

GIVEN UNDER MY HAND AND SEAL OF OFFICE, this the 24th _____, 1998.

PATRICIA M. REVNOLDS

Commission Expires:

SCHEDULE 1 TO ASSIGNMENT

INVENTION

This invention provides a medical method for: (1) prevention of life threatening hypothermia; (2) enhancing magnetic resonance spectroscopy and positron emission tomographic metabolic imaging; and (3) treatment of resistant neoplastic and infectious disease by concurrent administration of dinitrophenol [or other mitochondrial thermoregulatory uncoupling agents, e.g., carbonylcyanide m-chorophenylhydrazone (CCCP), carbonylcyanide-p-trifluoromethoxy-phenylhydrazone (FCCP), recombinant brown fat type protein, or lipid proton ionophores] and respiratory oxygen, intravenous fluids, anti-platelet drugs, as needed cooling, and specific metabolic, activating cytokines [e.g., recombinant tumor necrosis factor (TNF), interferons, etc.], hormones (e.g., glucagon), and other medications to control and focally enhance the mitochondrial uncoupling effects.

The present invention avoids the use of labor intensive, complex hyperthermia equipment, including invasive extracorporeal perfusion, with its associated thermal gradient toxicity problems to interposed normal tissues, inherent to all therapeutic methods of delivering heat from the outside-in. A new use(s)/method of generating intracellular oxygen derived free radicals, and heating from within the cell has been discovered for dinitrophenol (or other oxidative phosphorylation uncouplers) in prevention of cold injury, and treatment of free radical-thermosensitive parasites (e.g., Echinococcus), bacteria (e.g., Borrelia burgdorferi), lipid enveloped viruses (e.g., HIV), and neoplasia (e.g., gastric adenocarcinoma). It has further been discovered that cataracts, induced by dinitrophenol in the treatment of chronic obesity, can be prevented by concomitant administration of a variety of free radical scavenging agents, including tocopherol, ascorbic acid, and beta-carotene.

Briefly, the present invention is a new use(s)/method of inducing increased, intracellular free radical flux and hyperthermia, including the procedure of administrating dinitrophenol to patients in doses sufficient to denature and inactivate targeted biologic systems. Concurrent administration of tissue selective activating hormones, biologicals or drugs permits greater enhancement of the therapeutic index, while physiologic gain cooling, fluids, respiratory oxygen, and monitoring procedures permit safe therapeutic control. The figure on the attached page depicts an example use(s)/methodology of this process in an algorithm.

MEDICAL USES DWS-IN & S-ZaBAK >-PARASITIC (See Illustrative Example) (dosage/frequency of 41.5°C/1 hr (or less) BACTERIAL (3orcelia burgdorferi) 93-5hr for 2x-VO, uncoupling agent will be determined by the specific agent treated 42°C/2 to 8 hrs (or less) VIRAL (HIV) & use of modulating, Based on predictive biopsy and use of radiacion. MEDFLASTIC enhancing, or other combined therapy drugs. chemotherapy or biologic response modifiers

A 52 year old white Swiss male, hunting dog trainer, presented with right upper quadrant abdominal pain. History revealed past(24 month old) hepatic "cyst" surgery and treatment with albendazole(only I dose was given because of anaphylactic reaction). He denied history of weight loss, pulmonary, cardiac or neurologic disease. Upon physical examination, he had a weight of 198 pounds (90 Kg), height of 5'll", blood pressure 140/80, pulse-76 and regular, respirations 18/minute, and oral temperature of 37.3°C. Laboratory studies, including hepatic, renal, pulmonary and cardiac function tests were normal; complete blood count was unremarkable except for 20% eosinophilia. Ultrasound and nuclear magnetic resonance of the liver revealed 4 (2-3 cm. in diameter) cysts in the mid-right lobe; ELISA serology showed a diagnostic titer specific for Hydatid disease with Echinococcus multilocularis. The patient refused to entertain any additional surgery or albendazole therapy.

After clinical assessment and treatment evaluation, i.e., Echinococcus multilocularis protoscoleces and germinal layers are destroyed at 41°C/15 minutes, whereas liver-hepatocytes withstand temperatures of 42°C to 44°C for known periods of 20 hours and 15 minutes respectively, the patient was given 1 aspirin; 10 mg. diazepam by mouth; and, intravenous fluids of 0.85 normal saline containing 9 millimolar K PO, 7 milliequivalents of K⁺, and 2cc of 50% saturated solution of Mg_SO₄/liter, were infused at a rate of 12cc/kg/hr. Urine output was maintained at 1cc/kg/hour or greater. Esophageal (optional), rectal and foley (16 gauge) tipped bladder catheter thermistors gave temperature readings every two minutes within 0.1°C. Cardiac rate, rhythm, blood pressure, and repiratory rate sensors were placed and continously displayed on a multichannel monitor. Intravenous glucagon-2mg/hr was infused, with 1 mg given prior to DNP.

The patient was covered with a water absorbing polyethelene lined blanket, and baseline respiratory gas flow/oxygen consumption (VO₂) was determined using a 3 minute bag collection. Five minutes after intravenous administration of 90 mg of dinitrophenol (2% DNP/5% NaHCO₃ at 1 mg/kg), and determination that there was no untoward or idio-. syncratic reaction, an additional 90 mg of 2,4 dinitrophenol (total of 180mg, 2mg/kg body weight) was infused. Monitored physiologic parameters are shown in the Table below. An additional VO₂ rate was obtained five minutes after the second dose of DNP and the patient was thereafter placed on 100% O₂ via nasal canula. Target core temperature was maintained by occasional exposure of a limb and/or decreasing the glucagon infusion rate to 0.25 mg/hour. After the patient was maintained at a core temperature of 41.3°C for 20 minutes, the treatment was terminated by removing the blanket and permitting evaporative and radiant heat loss to return the body temperature to a normothermic level.

TABLE

Monitored Clinical Data On Mitochoodrial Uncoupling Use/Method In Illustrative Example

(Treatment of Mydatid disease-Echinococcus multilocularis)

Time (sinutes)	Hedication (1474 & dose)	Resp. Race-0 (breaths/min)	Consumption (al/min)	Cardiac Rate (beats/min)	Urine Output (cotal ml)	Core Temp.	Other (resurks)
-60	f.v. Fluids832 NS # 0.8 L/hour	15	290	7\$	•	37.1	Fluids @ 10-12cc per kg/hour.
-30	Glucszon-IV Orip 3 Zag/hour	20	-	75	47	37.1	Repatic Krebs Cycle scipulation.
0	2,4-dinterophenol-90mg IV in 4.5ml of SINANCO	20	-	58	53	37.4	Covered with poly- ethylene blanket.
2	[prepared by dissolving 2.3gm DN7(131 H ₂ O) in 31 NaHCO ₃ -giving 22 solution		330	. 92	-	37.8	increased 0, con- sumption precedes temp. elevation.
5	2.4-dimitrophenol-90cz IV in 4.3al of SINAKCO ₃	25	•	98	-	37.5	
10	Fluids increased to 1.2 L/hour; start Og	30	630	1:0	15	39.4	After VOzdeceralaed 1001 02 9 4 L/min
20	•	30	-	129	13	40.3	via našal cannula.
40	Glucagon -: 7 Jelp decreased to 0.3eg/hr	30	-	i 1d	25	41.4	Lover extremity is partially exposed.
60	Glucason discontinued	30	•	140	3¢	41.2	Blanket removed
120	[V fluid disconcinued	24	-	100	93	38.4	All thermistors

If Variations of the above use/method, i.e., protocol evaluation, monitoring, medications/dosages, time & comperature of mitochondrial uncoupling, will be necessitated by clinical and targeted biologic system treatment factors. Such variations for treatment of other parasicic (e.g. Halaria), bacterial (e.g., lyoe, Hansons disease), viral (e.g., H(V) and neoplastic disease will occur to those skilled in the art of medicine, and will be more fully described in the patent application.

	·	·
		• • • • • • • • • • • • • • • • • • •
	The DATENT OFFICE placed have	an antinous de donc en actor of:
	The stamp of the PATENT OFFICE, placed here Applicant Bachynsky et al.	on, acknowledges receipt or: By Fox/Delgado
	Serial No. PCT/US99/16940	Atty Docket # P01615WO0
	Deposit/Mail Date 07/17/2000	Client # 09805783 (Tx Pharmaceutica
• •	Depositivian Date	
	□ Amendment	 Information Disclosure Statement
	 Amendment after Final 	□ Form PT0-1449, References
£\$	□ Appeal Brief, O Copies	□ Issue Fee Transmittal
	 Application for Patent including 	□ Notice of Appeal
	0 Pgs Spec., 0 Claims	⊠ Postcard
	Assignments (1 for Bachynsky; 1 for Roy)	Power of Attorney by Assignee(s)
	Assignment Cvr Page (Form PTO-1595) 1	
	Cert. Of Exp. Mail under 37 CFR § 1.10	Preliminary Amendment
	Express Mail No	Priority Document
	© Cert. Of Mailing under 37 CFR § 1.8(a)	Req. for Filing [Cont.] [CIP] [Div. App.]
•	m Chael for a no an	p.] under 37 CFR § 1.53(b) Filing CPA under CFR § 1.53(d)
	harran acknowledges receipt of:	46 A! = 0
he stamp of the PATENT OFFICE, placed	By <u>Fox/Delgado</u>	ion of Missing Parts
pplicant Bachynsky et al.	Atty Docket # P01615W00	ttal Letter (In duplicate) Statement to Establish Small Entity
erial No. PCT/US99/16940		maceuticas) Statement to Establish Small Entity
Deposit/Mail Date 07/17/2000	Client # 09805783 (TXT)	9)
	 Information Disclosure Statement 	t
Amendment	Form PTO-1449, Reference	es
Amendment after Final	Issue Fee Transmittal	
Appeal Brief, O Copies	Notice of Appeal	
Application for Patent including	⊠ Postcard	
O Pes Spec., O Claims	- CANA by Assigned(s)	· .
Assignments (1 for Bachynsky; 1 for	to j	
Assignment Cvr Page (Form PTO-1	- Walana Amandmont	
Cert. Of Exp. Mail under 37 CFR § 1.10	Priority Document	
	Reg. for Filing [Cont.] [CIP] [Div.	. App.]
© Cert. Of Malling under 37 CFR § 1.8(" fNew App.1 under 37 CFR § 1.5	3(b)
© Check for \$ 80.00	Rea, for Filing CPA under CFR §	1.53(d)
Deposit Account No. 06-02375 for \$	 Submission of Missing Parts 	•
Declaration	Transmittal Letter (in duplica	te)
Drawings O Sheets,	Uverified Statement to Establish	Small Entity
O formal; O Informal		•
Extension of Time	A THE COMME	<u> </u>
Other	VI PCT/PTO 2 1 JUL 2000	
747 (15)	M. M	



Exhibit 2

			OIA		-		
	I.	NVENTOR DECLAR		Attorn 9857830	ey Docket No. 190161i5 us a)		
As a below na	med in	entor, I hereby declare th	nat:				
My residence,	post of	fice address and citizensh	ip are as stated below next to	o my name.			
inventor (if pl	ural na	mes are listed below) of ti	tor (if only one name is listed ne subject matter which is cl Intracellular Hyperthermia",	aimed and for which	th a patent is sought		
(check one)	Ø	is attached hereto.					
		was filed on as Appl and was amended on _					
		nave reviewed and unders y any amendment referre	tand the contents of the abo	ve identified specif	ication, including the		
		ty to disclose information 37, Code of Federal Regu	which is material to the exa dations, § 1.56(a).	mination of this ap	oplication in		
application(s) at least one co foreign applic	for pate ountry o ation fo	ent or inventor's certificate ther than the United Sta	Citle 35, United States Code, te, or § 365(a) of any PCT in tes of America, listed below a tificate, or of any PCT interests claimed:	ternational applica and have also ident	tion which designated ified below any		
Prior Foreign	Applica	tion(s)		Prior	ity Claimed		
(Numbe	r)	(Country)	(Day/Month/Year Filed)	⊃ Yes	□ No		
·					Ö		
(Numbe	r)	(Country)	(Day/Month/Year Filed)	Yes	No		
(Numbe	r)	(Country)	(Day/Month/Year Filed)	□ Yes	□ No		
I hereby clain application(s)			ed States Code § 119(e) of a	ny United States p	rovisional		
(Applicat	ion Seri	al No.)	(Filing Date)				
(Applicat	ion Seri	al No.)	(Filing Date)	•	•		
of any PCT is	iternati r of sac	onal application designati h of the claims of this app	ed States Code §120 of any l ng the United States of Ame blication is not disclosed in \$1 the paragraph of Title 35, U.S.	rica, listed below a 18 prior U.S. or PC	nd insofar as the T international		

of any PCT international application designating the United States of America, fiscal delow and insofar as the subject matter of each of the claims of this application is not disclosed in the prior U.S. or PCT international application in the manner provided by the first paragraph of Title 35, U.S.C. §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

(Application Serial No.)

(Filing Date)

(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)

(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Ful Name of Sole of First Investor Nicholas Bachynsky	invested Street Colors		7-24-98	
Rauma Texarkana, Texas		Citizerabip U.S.	, , , ,	
Part Office Address		L		
Same as above				
Till Name of Second Inventor Woodie Roy	Marde Examples		7-24-98	
Residence	<i>J</i> .	Chicatalia U.S.		
Post Office Address				
Same as above				
Full Name of Third (measter	Investice Signature		Cour	
Residence		Cingorabiy		
7sat Office Address				
Fell Name of Fourth Inventor	Inventar's Signature		Oate	
Partisees	A	Citteenainp		
Post Office Address		<u></u>		
Pull Name of Fifth (nysoter	Imentare Elmature		Date	
S. S	Fill Artist & A. d. Ing. 1915			
Rusidanto		Citizetiship		
Pas: Office Address				
Full Name of Sixth Inventor	Inventor's Signature		Data	
ReiZonce		Cituecania		
Peak Office Address				
Pull Name of Seventh Inventor	Invantac's Signature		Dato	
Residence	<u> </u>	Citizerality		
			<u> </u>	
Post Office Address				
Full News of Eighth Inventor	Emelitaria dignastura		Cata	
Residance	·	Cittemahip		
Post Circo Adires		<u> </u>		

#4



Please type a plus sign (e) inside this box		Approved for us	PTO/SB/01 (03-01) a through 10/31/2002. CMB 0661-0032	
Under the Paperwork Redu		U.S. Patent and T ad to respond to a collection of	rademark Office Information unle	b) U.S. DEPARTMENT OF COMMERCE SE IT CONTAINS & YEAR OMB CONTROL NUMBER.	
DECLARATION FOR		Attorney Docket Nu		HO-P01615US1	
	PATENT APPLICATION	First Named Invento	r Nich	olas Bachynsky	
	guage Declaration		OMPLETE I		
(37 C	SFR 1.16(e))	Application Number	09/744,62	2	
Declaration Submitted	X Declaration Submitted atter Initial	Filing Date	January 26	5, 2001	
with Initial OR	Filing (surcharge (37 CFR 1.18 (e))	Group Art Unit	N/A	·	
	required)	Examiner Name	Not Yet As	signed	
My mailing address is s As assignee, it is believed claimed and for which a pa	As a below named assignee, I hereby declare that: My mailing address is stated below. As assignee, it is believed that the inventors, Nicholas Bachynsky and Woodle Roy, are the original and first inventors of the subject matter which is claimed and for which a patent is sought on the inventor entitled: CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA				
I acknowledge the duty continuation-in-part app the national or PCT inte. I hereby claim foreign prinventor's or plant dread country other than the U application for patent in	eto MVDD/YYY) 01/26/200	ontents of the above identice. nuterial to patentability as ch became available betwation-in-part application. 9(a)-(d) or (7), or 365(b) of any PCT international identication in part application.	of any foreign at application will	CFR 1.56, including for date of the prior application and polication(s) for patent, hich designated at least one	
Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYY)	Priority Not Claimed	Cortified Copy Attached? YES 840	
Addistonas foreigi	Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached herato:				
I hereby certify that this co	Occiaration for Util	ity or Design Patent Appl	leation		
below.	prespondence is being deposited with the service in an envelope addressed to:	im the U.S. Postal Service. Commissioner for Patonia	aa Express Mai 4, Washington, I	l, Airbill No. DC 20231, on the date shown	
Dated: September 5, 2001	7	TASK		. !!	
	91g(m) (a)		(han)	(E. Krieger) & No.25, 887	



•	60/094,286	07/27/98
	(Application No.)	(Filing Date)
	(Application No.)	(Filing Date)
	(Application No.)	(Filing Date)
Additio	nal U.S. provisional applications are lia	eted on a supplemental data sheet attached hereto.
with the know imprisonmen	irrnation and belief are believed to be t viedge that willful false statements and	my own knowledge are true and that all statements rue; and further that these statements were made the like so made are punishable by fine or nat such willful false statements may jeopardize the ion.
Address: Date:	701 W. 14 th Street Texarkana, Texas 75501 9-4-01	Names James J. Naples The President
or and a second		